Login
$INAB
$0.75 -$0.07 (8.05%) After hours

$INAB 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

06 Aug 2026 8-K: Results of Operations and Financial Condition

Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half...

01 Jun 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

IN8bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:

07 May 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

(a) Successor to and Continuation of Prior Plans. The Plan is the successor to and continuation of the Prior Plans. As of the Effective Date, (i) no additional awards may be granted under the Prior Plans; (ii) the Prior Plan’s Available ...

12 Mar 2026 8-K: Results of Operations and Financial Condition

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

27 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

09 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

19 Dec 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 18, 2025, by and among IN8bio, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an ...

24 Nov 2025 8-K: Other Events

IN8bio, Inc. (the “Company”) presented consolidated data, a summary of which is located below, from its investigator-sponsored Phase 1 single-center clinical trial of INB-200 and its Company-sponsored Phase 2 multi-center clinical trial ...

06 Nov 2025 8-K: Results of Operations and Financial Condition

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential t...

27 Oct 2025 8-K: Other Events

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.

30 Jun 2025 8-K: Other Events

On June 24, 2025, IN8bio, Inc., a Delaware corporation (the “Company”), received a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), w...

04 Jun 2025 8-K: Material Modification to Rights of Security Holders

(Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

02 Jun 2025 8-K: Other Events

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol

09 May 2025 8-K: Submission of Matters to a Vote of Security Holders

IN8bio, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on May 8, 2025. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth...

07 May 2025 8-K: Results of Operations and Financial Condition

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as pre...

28 Apr 2025 8-K: Other Events

First gamma-delta (gd) TCE to demonstrate significant gd T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS)

28 Apr 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

To the Holder of Series A and Series B Warrants to Purchase Common Stock

13 Mar 2025 8-K: Results of Operations and Financial Condition

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support